Consensus Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
19.92 USD +0.45% Intraday chart for Veracyte, Inc. +5.62% -27.59%

Evolution of the average Target Price on Veracyte, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6bcda1568c8ec3e23af7880486b4e072._41yzoGO7ZLIN_1uWTzufEJVDjMTjhpuk8CfW1_6CSw.yfUwpfW9rvWHfocUM2-vOSUPY1JCy0Mjq4_yGBOIcRm69RCk18-l_qp2lg~9da1b0d909d85a55c91255392443c86b
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating MT
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating MT
Goldman Sachs Cuts Veracyte's Price Target to $32 From $37, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Veracyte to $23 From $22, Maintains Underweight Rating MT
Needham Adjusts Price Target on Veracyte to $35 From $34, Maintains Buy Rating MT
Needham Adjusts Price Target on Veracyte to $34 From $33, Keeps Buy Rating MT
Raymond James Downgrades Veracyte to Market Perform From Outperform MT
Scotiabank Initiates Veracyte at Sector Outperform Rating With $33 Price Target MT
Scotiabank Initiates Veracyte at Sector Outperform With $33 Price Target MT
Raymond James Adjusts Price Target on Veracyte to $27 From $31, Maintains Outperform Rating MT
SVB Securities Adjusts Veracyte's Price Target to $35 From $30, Keeps Outperform Rating MT
Needham Adjusts Price Target on Veracyte to $33 From $31, Maintains Buy Rating MT
Raymond James Adjusts Veracyte's Price Target to $31 from $30 Keeps Outperform Rating MT
Goldman Sachs Cuts Price Target on Veracyte to $32 From $35, Noting Decline in Peer Multiples; Buy Rating Maintained MT
Needham Adjusts Veracyte's Price Target to $31 From $26, Citing 'Peer Multiple Expansion,' Reiterates Buy Rating MT
Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating MT
Raymond James Adjusts Veracyte's Price Target to $30 from $34, Keeps Outperform Rating MT
Needham Adjusts Veracyte's Price Target to $26 From $31 on Peer Multiple Compression, Reiterates Buy Rating MT
Needham Adjusts Veracyte's Price Target to $31 From $35, Citing 'Peer Multiple Compression,' Reiterates Buy Rating MT
Stephens Adjusts Veracyte Price Target to $44 from $52, Keeps Overweight Rating MT
Lake Street Lowers Veracyte's Price Target to $50 From $95, Maintains Buy Rating MT
Raymond James Cuts Veracyte's Price Target to $34 From $62, Reiterates Outperform Rating MT
SVB Leerink Adjusts Veracyte's Price Target to $40 from $45, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
19.9 USD
Average target price
30.83 USD
Spread / Average Target
+54.94%
High Price Target
37 USD
Spread / Highest target
+85.93%
Low Price Target
21 USD
Spread / Lowest Target
+5.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Veracyte, Inc.

Goldman Sachs
Morgan Stanley
Needham & Co.
Raymond James
Scotiabank
SVB Securities LLC
Stephens Inc.
SVB Leerink
Lake Street
Truist Securities
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. Consensus Veracyte, Inc.